Radiolabeled Peptide as Diagnostic, Therapeutic, and Theranostic agents for Prostate Cancer: Systematic Literature Review
Abstrak
Prostate cancer (PCa) is the most common sex-related malignancy and the second most common cause of mortality
after lung cancer for men. Around 61.8% of Indonesian people undergo cancer treatment with surgery. This study aimed to figure
out the use of radiolabeled peptides for diagnosis, therapy, and theranostics of prostate cancer. This study performed a literature
review by searching the web databases such as PubMed, MDPI, Elsevier (Science Direct), and ACS Publications. The result showed
that peptide compounds such RM2, VCN (Vicrostatin), DB15, and BBN7-14 were utilized as radionuclide-carriers for diagnostic
imaging, meanwhile, peptides such as NeoBOMB1, PSMA-617, and [RGD-Glu-[DO3A]-6-Ahx-RM2] containing alpha or betaemitted radionuclide were used as therapeutic and theranostic agents. They were tagged using 68Ga, 161Tb, 177Lu, 64Cu, 124I, 99mTc,
90Y, and 86Y radionuclides. Great efforts have been conducted in developing peptide-based radiopharmaceuticals for diagnosis and
therapy of prostate cancer. Research groups focusing in nuclear medicine will continue to develop radiopharmaceuticals in the
future, especially radiopeptide compounds for the diagnosis and therapy of prostate cancer.
after lung cancer for men. Around 61.8% of Indonesian people undergo cancer treatment with surgery. This study aimed to figure
out the use of radiolabeled peptides for diagnosis, therapy, and theranostics of prostate cancer. This study performed a literature
review by searching the web databases such as PubMed, MDPI, Elsevier (Science Direct), and ACS Publications. The result showed
that peptide compounds such RM2, VCN (Vicrostatin), DB15, and BBN7-14 were utilized as radionuclide-carriers for diagnostic
imaging, meanwhile, peptides such as NeoBOMB1, PSMA-617, and [RGD-Glu-[DO3A]-6-Ahx-RM2] containing alpha or betaemitted radionuclide were used as therapeutic and theranostic agents. They were tagged using 68Ga, 161Tb, 177Lu, 64Cu, 124I, 99mTc,
90Y, and 86Y radionuclides. Great efforts have been conducted in developing peptide-based radiopharmaceuticals for diagnosis and
therapy of prostate cancer. Research groups focusing in nuclear medicine will continue to develop radiopharmaceuticals in the
future, especially radiopeptide compounds for the diagnosis and therapy of prostate cancer.
Kata Kunci
Radiolabelled-peptide; therapy; diagnosis; prostate cancer.